SLAS 2022 – HTS Assays and Discovery Services
BellBrook Labs will exhibit and present posters at the upcoming SLAS 2022 conference in Boston, MA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting kinases involved in the innate immune response, navigating hit prioritization after screening using biochemical assays, assay development, lead discovery services, and more!
SLAS 2022 Conference
Boston Convention & Exhibition Center
Boston, MA USA
February 5th-9th
Visit Booth #410 for Chocolate and Lively Discussion!
Poster Presentations
Targeting OAS1 with the Transcreener 2-5A OAS Assay
Targeting Kinases Involved in Innate Immunity with the Transcreener ADP Assay
Available Guides / Application Notes
Targeting Kinases Involved in the Innate Immune Response
Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterization of small molecule modulators have aided these efforts. The Transcreener ADP² Kinase Assay meets this need as it relies on direct ADP detection to measure the activity of virtually any kinase. The method has been extensively validated for kinase discovery programs since 2007. This article provides five examples of how Transcreener allowed rapid assay development to enable screening and dose-response measurements.
A Guide to Navigating Hit Prioritization After Screening Using Biochemical Assays
So you have performed your screen. What’s next? This guide is focused on how biochemical assays are used for characterizing and prioritizing compounds following a primary screen with an enzyme target, whether using high throughput screening (HTS) or virtual screening (VS). A typical screening funnel is shown below, with the many applications of the biochemical activity assay highlighted.
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
During drug development initiatives, analysis of drug-target residence times can improve efficacy, increase therapeutic window, and reduce the risk of premature focus on candidate compounds that are likely to have undesirable side effects. This guide provides technical background on concepts and techniques for use of Transcreener® biochemical assays to measure drug-target residence times, along with examples and case studies.
